Hurley Capital LLC Buys New Holdings in Penumbra, Inc. (NYSE:PEN)

Hurley Capital LLC purchased a new position in Penumbra, Inc. (NYSE:PEN) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 230 shares of the company’s stock, valued at approximately $56,000.

Other institutional investors also recently bought and sold shares of the company. Cerity Partners LLC lifted its holdings in shares of Penumbra by 19.2% in the 3rd quarter. Cerity Partners LLC now owns 3,612 shares of the company’s stock valued at $702,000 after buying an additional 583 shares during the period. Paloma Partners Management Co purchased a new stake in Penumbra in the 3rd quarter worth approximately $253,000. HighTower Advisors LLC boosted its position in Penumbra by 2.3% in the 3rd quarter. HighTower Advisors LLC now owns 5,792 shares of the company’s stock worth $1,128,000 after purchasing an additional 128 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Penumbra during the 3rd quarter valued at approximately $304,000. Finally, Quantinno Capital Management LP acquired a new position in shares of Penumbra in the 3rd quarter valued at $294,000. 88.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. UBS Group raised their price target on shares of Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Citigroup lifted their price target on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and set a $330.00 price target (up previously from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Robert W. Baird boosted their price objective on Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $294.47.

Insiders Place Their Bets

In other news, EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00. Following the transaction, the executive vice president now owns 66,539 shares of the company’s stock, valued at approximately $19,125,304.77. The trade was a 0.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Arani Bose sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total transaction of $3,405,240.00. Following the sale, the director now owns 314,819 shares of the company’s stock, valued at approximately $89,336,187.63. The trade was a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 111,236 shares of company stock valued at $31,222,390. Insiders own 5.00% of the company’s stock.

Penumbra Stock Performance

PEN opened at $262.37 on Friday. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The firm has a market capitalization of $10.11 billion, a PE ratio of 771.66, a PEG ratio of 2.83 and a beta of 0.51. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average price is $274.48 and its 200 day moving average price is $245.61.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. As a group, sell-side analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.